P. Rijnbeek

First name
P.
Last name
Rijnbeek
Raventós, B., Català, M., Du, M., Guo, Y., Black, A., Inberg, G., et al. (2023). IncidencePrevalence: An R package to calculate population-level incidence rates and prevalence using the OMOP common data model. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5717
Li, X., Burn, E., Duarte-Salles, T., Yin, C., Reich, C., Delmestri, A., et al. (2022). Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. Bmj, 379, e071594. http://doi.org/10.1136/bmj-2022-071594
Burn, E., Li, X., Kostka, K., Stewart, H. M., Reich, C., Seager, S., et al. (2022). Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: Incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiol Drug Saf, 31, 495-510. http://doi.org/10.1002/pds.5419
Lane, J. C. E., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T. F., Alghoul, H., et al. (2020). Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology (Oxford). http://doi.org/10.1093/rheumatology/keaa771
Lane, J. C. E., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T. F., Alghoul, H., et al. (2020). Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol. http://doi.org/10.1016/s2665-9913(20)30276-9
Li, X., Ostropolets, A., Makadia, R., Shoaibi, A., Rao, A., Sena, A. G., et al. (2021). Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. http://doi.org/10.1136/bmj.n1435